# Skeptical journal review and prioritized revision requirements

Review date: October 10, 2026. The review was undertaken before repository cleanup; internal snapshots are not distributed with the public portfolio. This review distinguishes observed defects from inherent limitations. Recommendations below were written before running the revised analyses; disposition and actual results will be appended after execution.

**Editorial recommendation:** Not acceptable as an original research article in its submitted form. Major methodological and reporting revision is needed. Even after computational repair, a reputable journal may reject it for limited scientific advance and single-cycle precision. It remains useful as a transparent research-training/reproducibility project. Statistical significance would not remedy those limitations.

**Verification scope:** I inspected the protocol, manuscript, Python processing/inference/pipeline, R reference code, tests and recorded outputs. Prior executed Python/R comparisons support agreement for the quantities they compare; this is not a fresh external reproduction, peer review certification, or proof that a shared formula is correct. Revised execution results will be reported only after the relevant commands run. Literature access was focused and sometimes abstract/metadata-only; no exhaustive novelty assessment or inaccessible full-text review is claimed.

## Evaluation of the ten requested domains

| Domain | Assessment of submitted study | Required response |
|---|---|---|
| 1. Novelty/importance | Clinically and publicly relevant topic, but insurance-related awareness gaps are already established. One historical cycle and more reproducible software are insufficient to establish an original epidemiological discovery. | Position as a historical descriptive replication/extension; articulate ascertainment sensitivity as the limited contribution. Do not claim publication readiness. |
| 2. Research question | Valid as an association between current insurance and reported lifetime diagnosis within an operational case domain. It cannot answer whether coverage caused detection, access failure or untreated disease. | State the observed-data estimand, historical target and temporal mismatch explicitly; remove “confirmatory-style” implications for reviewer-triggered analyses. |
| 3. Selection | Requiring complete BP even for current-medication cases discards 35 known eligible adults, a restriction not required by the case definition. Case selection is itself affected by awareness/treatment/insurance. Missing examination BP and unknown medication also leave some target cases unclassifiable. | Admit medication-confirmed cases without BP in revised primary analysis; retain the old restriction as sensitivity; report unresolved ascertainment and examined-domain bounds. Do not claim selection bias disappears. |
| 4. Exposure/outcome | HIQ011 and BPQ020 are correctly mapped, and BPQ040A/050A skips are respected. However current coverage is compared with “ever told,” benefit quality/coverage duration are unmeasured, and medication-only cases are aware by questionnaire linkage. Single-visit elevation is not confirmed clinical hypertension. | Keep recognition-proxy language; quantify component mix; consider an available coverage-continuity restriction using HIQ210 without misinterpreting skips. No invented medication or diagnosis error is alleged. |
| 5. Confounders | Age, sex and SES/social classifications are reasonable association-adjustment variables. The diagram does not identify a sufficient causal adjustment set; current PIR may follow illness/coverage. Race categories must not be interpreted biologically. | Describe covariate-adjusted associations, not “confounding eliminated.” Preserve the specified model; retain functional-form and omit-PIR sensitivities rather than collapse groups to obtain significance. |
| 6. Survey inference | Positive MEC full-design domain estimation and Taylor score variance appear appropriate and already agree numerically with R for recorded quantities. Residual df=3 is a conservative supported convention, not a coding error; software guidance warns that it may be conservative for individual-level covariates. Marginal df=15 vs coefficient df=3 is insufficiently defended; shared custom marginal influence formulas are not an independent method check. | Harmonize primary marginal inference with the model residual reference, report explicit alternative design-df calibration without selecting by p value; add stratified delete-one-PSU R replicate validation of nonlinear standardization. Test PSU retention, not just a hardcoded expected df. |
| 7. Missingness | Roughly one in eight complete-exposure/outcome records is dropped for covariates, chiefly PIR. Weighted profile comparison is descriptive, not a missing-data bias correction; tiny awareness-missing bounds do not address missing income. | Add a model-based missing-PIR response-weighting sensitivity, refitting nuisance and outcome models inside PSU replicates so SE include estimated-weight uncertainty. Explain MAR/positivity assumptions and the remaining education exclusion. MNAR cannot be identified from these files. |
| 8. Sensitivities | Threshold, reading, age and covariate variations are useful, but some change both the target domain and sample. “Measured-only bias correction” would be unsupported. Stability conclusions should not hinge on point-estimate sign or p values alone. | Distinguish original protocol sensitivities from post-review additions, use clear domain/denominator labels, and report uncertainty and influential units. Never interpret case-definition changes as independent studies or a validated bias cure. |
| 9. Interpretation | The submitted aOR 0.59 (CI 0.21–1.63) supports substantial uncertainty, not absence of an association. ORs are noncollapsible and cannot be explained purely as confounding by comparing nested models. Model standardization needs a named population and adequate support; small insurance-by-category cells limit it. | Retain inconclusive conclusions, discuss noncollapsibility and mixed case composition; identify standardization as model-dependent descriptive adjustment. Avoid claims of clinical detection failures or policy effects. |
| 10. Reproducibility/reporting | Strong source caching, tests, genuine R comparison, calculated figures and preservation. Gaps: core coding checks reuse Python-specified sensitivity masks; stale validation/clean-copy reports can survive a failed rerun; error stages are not always machine-recorded; there is no direct test for some reliability edge cases. | Independently reconstruct every regression domain in R, validate full covariance matrices as well as diagonals, fail closed on stale validation, improve runner failure/test reporting, test reliability and classification edge cases, regenerate all dependent narrative. |

## Prioritized major changes

### P1 — Correct avoidable participant exclusion and distinguish targets

**Required:** Medication-confirmed cases without BP should not be rejected by an operational definition that includes medication. Revise primary eligibility, preserve the old BP-complete analysis, report examined target, ascertainment-known, case and model counts separately, and bound quantities affected by unknown ascertainment. Do not allow primary hypertension prevalence to imply all examined or all U.S. adults are observed completely. Known medication users lacking BP should have missing BP in Table 1 rather than fabricated values. A single cutoff crossing is not a clinical diagnosis.

**Cannot be removed:** Awareness/treatment-linked case selection and missing examination participation. Measured-only domains remove controlled treated adults and may create different selection. Restricting the study does not resolve that causal problem.

### P2 — Address income-related analytic selection with honest uncertainty

**Required:** Execute a response-weighting sensitivity among outcome/exposure- and non-PIR-covariate-complete eligible adults. Include observed outcome/exposure, demographics, available auxiliary measurements and design-weight information in the response model. Estimate survey-weighted score point estimates, show response probability/weight diagnostics, and refit the response model in every sampling-unit replicate. Report complete cases and weighted sensitivity together. Do not present fixed estimated response weights as known or an ordinary GLM SE as survey inference.

**Cannot be removed:** The MAR assumption that missing PIR is independent of true PIR given included observed variables, unmeasured selection and one missing-education case. No method can verify MAR or recover longitudinal coverage history from these files. Multiple imputation is not mandatory if a transparent, adequately caveated alternative sensitivity is implemented.

### P3 — Defend inferential references and independently check marginal variance

**Required:** State full design and model residual reference df separately. Use the same conservative residual reference for primary coefficient and model-standardized contrasts; bounded probability CIs should use a transformation rather than silently clipping. Report design-df=15 alternatives as explicit reference-distribution sensitivities, not changed SE or an automatic correction. Add R JKn estimates of nonlinear probabilities/contrasts and explain that jackknife and Taylor need not match exactly. Match complete covariance matrices for equivalent Python/R Taylor models.

**Not a claimed error:** The existing stratified/clustering variance is not ordinary weighted regression, and no evidence establishes that its recorded coefficient SE were wrong. Nor does adding individual covariates literally reduce the number of physical PSUs; residual df is a reference calibration. Conservative df may limit power without proving model overfitting.

### P4 — Incorporate cycle-specific survey guidance and limit national claims

CDC investigated declining response and unusual sampled-location characteristics in 2017–2018, incorporated enhanced education/income calibration, and recommended combining with earlier cycles to reduce remaining representation error ([official summary](https://wwwn.cdc.gov/nchs/data/nhanes/analyticguidelines/17-18-sampling-variability-nonresponse-508.pdf)). The submitted report does not address this specific concern. **Required:** Cite it, confirm released MEC weights are used without claiming no original nonresponse adjustment, and clarify that later item missingness is separate. Keeping the requested single cycle is permitted, but national/historical inference must be qualified. A pooled extension would require a new target/time period and protocol, not silent cycle mixing.

### P5 — Strengthen validation independence and reporting integrity

**Required:** R should reconstruct case/reading/age/coverage/complete-case masks independently, not accept all exported domain columns unchecked. Add full covariance comparisons and direct reliability boundary/complement tests. A failed run must invalidate current validation claims and record its failed stage; a clean-copy claim must be tied to the actual source/input hashes. Regenerate protocol amendments, manuscript, README, QA and application materials. Preserve the submitted version and explicitly label post-review additions.

### P6 — Reframe scientific contribution

**Required:** Discuss the limited incremental contribution compared with the papers below. Remove “confirmatory-style” wording for analyses selected after reviewing results; avoid definitive attribution to insurance or claims that software agreement validates epidemiological assumptions. Add funding/authorship/ethics-status reporting without inventing an institutional determination. A defensible analysis may remain unpublishable in a selective journal because novelty and precision are not fixable by polishing.

## Minor concerns and unsupported implications

- Table 1 uses variable-specific denominators but printed n switches between category count and denominator. Display both explicitly, including missingness; medication-confirmed cases may lack BP.
- Number of “independent coefficients” is not a meaningful measure of epidemiologic rigor; report covariance/design support and actual checks instead.
- Crude versus adjusted OR differences combine adjustment, sample changes and OR noncollapsibility. The common-sample fits solve only the sample-change issue.
- “No category had a zero outcome” does not rule out multivariable separation or sparse combinations; inspect convergence, prediction/weighted influence and cross-classified support without claiming certainty.
- A single displayed maximum leverage is not a robustness analysis. The available linearized record influences and 30 PSU deletions are useful diagnostics, not proof of stability.
- Usual care (HUQ030) includes any reported routine place; the analysis cannot infer non-emergency primary care unless HUQ041 is used. Keep the general-place label.
- The primary 130/80 definition applied to historical diagnosis responses may include people not previously labeled hypertensive under older thresholds; 140/90 comparisons are informative but do not recover the diagnosis threshold used for each person.
- Boundary proportion intervals and complementary proportion screening require direct tests. Numeric NCHS screening is not formal agency clearance or a guarantee of valid regression inference.
- No unsupported novelty, causality, funding or publication claim was found in the existing summaries. The issue is limited publishable contribution and overly broad validation/confirmatory language, not fabrication of those claims.

## Comparison with verifiable published literature

| Reference | Relevant overlap | What this study adds / cannot claim |
|---|---|---|
| Egan BM et al. *The growing gap in hypertension control between insured and uninsured adults: NHANES 1988 to 2010.* Hypertension. 2014;64:997–1004. [PubMed](https://pubmed.ncbi.nlm.nih.gov/25185135/), [DOI](https://doi.org/10.1161/HYPERTENSIONAHA.114.04276). | Earlier nonelderly insurance-related care cascade, including awareness. Checked abstract/metadata. | The insurance-awareness association is not novel; this cycle/threshold is a descriptive update, not replication of identical estimands. |
| Duru OK et al. *Health insurance status and hypertension monitoring and control in the United States.* Am J Hypertens. 2007;20:348–353. [PubMed](https://pubmed.ncbi.nlm.nih.gov/17386339/), [DOI](https://doi.org/10.1016/j.amjhyper.2006.11.007). | Insurance and hypertension care in NHANES 1999–2002; different case ascertainment. | Historical recognition/control distinction remains; cannot claim first analysis of insurance and hypertension care. |
| CDC/NCHS. *Characteristics of U.S. Adults With Hypertension Who Are Unaware of Their Hypertension, 2011–2014.* Data Brief 278 (2017). [Official report](https://www.cdc.gov/nchs/products/databriefs/db278.htm). | Describes awareness differences by insurance and utilization. | Direct context, but not a numerical benchmark for this lower threshold, restricted ages or adjusted OR. |
| Calixte R et al. *Access to routine health care and awareness of hypertension status among adults: NHANES 2011–2018.* Preventive Medicine. 2024;179:107843. [DOI](https://doi.org/10.1016/j.ypmed.2023.107843), [author institution](https://researchconnect.suny.edu/en/publications/access-to-routine-health-care-and-awareness-of-hypertension-statu/). | Includes this survey period; examines routine-care access and awareness in ages 18–64 with multivariable Poisson analysis. Checked institution abstract/metadata. | The exploratory usual-care model is overlapping work, not an independent novel aim; populations and effect measures differ. |
| Muntner P et al. *Trends in blood pressure control among US adults with hypertension, 1999–2000 to 2017–2018.* JAMA. 2020;324:1190–1200. [PubMed](https://pubmed.ncbi.nlm.nih.gov/32902588/), [DOI](https://doi.org/10.1001/jama.2020.14545). | Historical care context through this cycle. | Control is not awareness; this one-cycle study cannot infer trends or ACA effects. |

Method sources: [CDC 2026 NHANES quality guidance](https://wwwn.cdc.gov/nchs/nhanes/QualityAnalysesGuidelines.aspx), [NCHS proportion standards](https://www.cdc.gov/nchs/data/series/sr_02/sr02_175.pdf), installed R survey 4.5 help/source for svyglm, as.svrepdesign and withReplicates, and [CRAN survey](https://cran.r-project.org/package=survey). Focused review is not an exhaustive search or a formal systematic review.

## Revision status

Pending execution at the time this review was written. A machine-generated disposition with actual changes, executed checks and unresolved limitations will be appended below after the revised pipeline runs. The review's criticisms of the submitted version will remain visible.

<!-- GENERATED_REVISION_DISPOSITION -->

## Executed revision disposition

This section was generated from the revised output files after required stages succeeded. All reviewer-directed additions are post-review/exploratory; initial concerns above describe the submitted version, not the repaired code.

| Priority | Implemented change and executed evidence | Remaining limit |
|---|---|---|
| P1 | Admitted 35 known-medication cases without BP; revised complete-case n=1,534, versus 1,503 in preserved BP-complete sensitivity. Reported 164 unresolved examined records and worst-case ascertainment bounds. | Treatment/awareness-linked case selection and examination nonparticipation are not fixed. |
| P2 | Executed R missing-PIR response weighting with 30 nuisance/outcome-refit JKn replicates; OR 0.66 (CI 0.29–1.51), 224 missing PIR records in target n=1,758. | MAR, model adequacy and unobserved positivity are unverified; 1 missing non-PIR record remains excluded. No independent Python IPW verification. |
| P3 | Harmonized primary marginal df=3 with regression; bounded logit probability intervals; full-design-df calibration reported; independent R JKn/Taylor SE ratios 1.001–1.018. | Small-sample reference choice and sparse support still require expert review; method agreement is not proof of zero bias. |
| P4 | Added CDC cycle-specific nonresponse/calibration guidance and conditional observed-data targets; retained the requested single cycle. | Residual representation error and original nonresponse cannot be removed with these files; pooling would require a new time-target protocol. |
| P5 | Independently rebuilt 21 R domains; compared 2,969 covariance entries (maximum absolute discrepancy 9.01e-12); added content fingerprints and fail-closed stage handling. 15 tests passed. | Validation scope is coding/numerical consistency and explicitly executed R replicates, not independent validation of all assumptions. |
| P6 | Reframed as historical descriptive replication; disclosed post-review changes, OR noncollapsibility, uncertainty, authorship/funding/ethics unknowns; regenerated writing and figures. | Limited scientific novelty and precision remain. Computational repair does not make a selective-journal original contribution. |

**Current primary result:** uninsured-versus-insured aOR 0.60 (95% CI 0.22–1.62), n=1,534, conservative residual df=3, p=0.201. This remains inconclusive, not evidence of no association.

**Executed verification:** 15 automated tests passed, 0 failures and 0 errors. R raw coding, all model domains, 235 coefficient rows/full covariance, descriptive estimates and model standardization were compared. R JKn standardization and PIR sensitivities each executed 30 refits. Missing-PIR weighting has no independent Python reproduction and is not described as one. Logs and outputs document these scopes.

**Unresolved requirements for journal submission:** demonstrated scientific advance; independent qualified epidemiology/survey review of targets, selection, inference reference and nuisance specification; justified sensitivity to MNAR and residual confounding; fuller literature search; actual applicant authorship/funding/conflict/institutional review information. No further available-code change can establish longitudinal insurance history, true clinical diagnosis, verify MAR or manufacture novelty. These remain explicit limitations rather than silently claimed solved.
